# AGRN Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *AGRN* gene encodes agrin, a large heparan sulfate proteoglycan crucial for neuromuscular junction (NMJ) organization, primarily by clustering acetylcholine receptors (AChRs) via interaction with LRP4 and MuSK. Pathogenic variants in *AGRN* are a significant cause of congenital myasthenic syndromes (CMS), often presenting with ptosis, ophthalmoparesis, and fatigable weakness.
- Agrin's function extends beyond the NMJ to include maintenance of the blood-brain barrier, cardiac contractility, and neurogenesis, with dysregulation implicated in Alzheimer's disease and chronic liver disease. Its role in basement membrane assembly and cell signaling highlights its broad biological importance.
- Alternative splicing of *AGRN*, particularly the inclusion of Z8 and Z11 exons, generates neural isoforms essential for high-affinity LRP4 binding and MuSK activation, a process regulated by PTBP1. Null variants in *AGRN* can lead to lethal fetal akinesia deformation sequence (FADS) due to complete loss of agrin function.
- Agrin is implicated in various malignancies, including colorectal, breast, and hepatocellular carcinoma, where its overexpression promotes tumor progression, invasion, and metastasis. Therapeutic strategies targeting agrin in cancer include monoclonal antibodies and siRNA/ASO therapies to suppress its expression.
- In the context of infectious diseases, plasma agrin levels are associated with COVID-19 hospitalization risk, potentially through interactions with viral entry mechanisms or immune modulation. Elevated plasma agrin also serves as a diagnostic biomarker for HBV-related chronic hepatitis and liver fibrosis.
- Therapeutic approaches for AGRN-related CMS include acetylcholinesterase inhibitors and MuSK agonist antibodies, which bypass the need for functional agrin by directly activating MuSK. Gene therapy using AAV vectors is under preclinical investigation for restoring agrin function.

---

## Executive Summary & Key Metadata

The **AGRN** gene encodes agrin, a large (~400–600 kDa) heparan sulfate proteoglycan (HSPG) that is a core organizer of the neuromuscular junction (NMJ) and a critical component of basement membranes (BMs) across multiple tissues. Agrin is best characterized for its instructive role in clustering acetylcholine receptors (AChRs) on the postsynaptic muscle membrane, a process mediated by its interaction with the lipoprotein receptor-related protein 4 (LRP4) and muscle-specific kinase (MuSK). Beyond the NMJ, agrin participates in the maintenance of the blood-brain barrier (BBB), cardiac contractility, hippocampal neurogenesis, and immune modulation. Pathogenic variants in AGRN cause congenital myasthenic syndromes (CMS), lethal fetal akinesia deformation sequence (FADS), and have been implicated in the pathogenesis of myasthenia gravis (MG), various malignancies, and chronic liver disease.

| Attribute | Detail |
|---|---|
| **HGNC Symbol** | AGRN |
| **UniProt Accession** | O00468 |
| **Representative PDB ID** | true (multiple domain structures available; see Section 2) |
| **Chromosomal Locus** | 1p36.33 (GRCh38: chr1:1,020,118–1,055,741; minus strand) |
| **Primary Molecular Function** | Heparan sulfate proteoglycan; AChR clustering at NMJ; basement membrane assembly; cell signaling via LRP4/MuSK and integrins |
| **Disease & Pathology Associations** | Congenital myasthenic syndrome (CMS), lethal fetal akinesia deformation sequence (FADS), myasthenia gravis (risk locus), Alzheimer's disease (AD), colorectal cancer, breast cancer, hepatocellular carcinoma, COVID-19 severity, chronic obstructive pulmonary disease (COPD) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human *AGRN* gene is located on the short arm of chromosome 1 at cytogenetic band **1p36.33**, one of the most gene-dense and disease-associated regions of the human genome. The reference genome assembly (GRCh38) places the gene between coordinates chr1:1,020,118 and chr1:1,055,741 on the minus (reverse) strand. The gene spans approximately **35.6 kilobases (kb)** of genomic DNA and contains **36 annotated exons** (Ensembl transcript ENST00000379370.8 for the canonical full-length isoform). The 5' untranslated region (UTR) is relatively short (~200 bp), whereas the 3' UTR extends for over 1.5 kb, containing multiple AU-rich elements (AREs) that may regulate mRNA stability.

Early characterization of the mammalian agrin gene by Rupp et al. (1992) using rat cDNA libraries demonstrated that agrin contains domains homologous to protease inhibitors, laminin, and epidermal growth factor (EGF)-like repeats, establishing the multidomain architecture that is conserved across vertebrates [1]. The human gene shares this organization, with the coding sequence (CDS) spanning approximately 6.3 kb and encoding a precursor protein of 2,045 amino acids (UniProt O00468, isoform 1).

### 1.2 Promoter Architecture and Regulatory Elements

The promoter region of *AGRN* lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island (CpG: 129) is subject to differential DNA methylation, which has been implicated in tissue-specific expression and in cancer. For instance, Titus et al. (2017) identified differentially methylated regions on 1p36 across breast cancer subtypes, with AGRN among the genes showing subtype-specific methylation changes [2].

Several transcription factor binding sites (TFBS) have been predicted and experimentally validated in the proximal promoter:

- **SP1 (Specificity Protein 1)**: Multiple GC-box motifs within the CpG island serve as SP1 binding sites, driving basal transcription.
- **E-box elements (CANNTG)**: Recognized by basic helix-loop-helix (bHLH) factors such as MyoD and myogenin in muscle cells, linking agrin expression to the myogenic program.
- **TEAD-binding sites**: The YAP1/TAZ-TEAD transcriptional network directly regulates synaptic gene expression at the NMJ, including AGRN. Gessler et al. (2023) demonstrated that muscle-specific knockout of *Yap1* or *Taz* in mice leads to reduced expression of agrin and other synaptic genes, confirming TEAD-dependent regulation [3]. Furthermore, TLE3 and TLE4, transcriptional repressors of canonical Wnt signaling, modulate postsynaptic transcription at the NMJ, and their knockdown alters AGRN expression levels [4].

### 1.3 Enhancer Elements and Long-Range Regulation

Chromatin conformation capture studies (Hi-C) in muscle and neuronal cell lines have identified putative enhancer elements within intron 1 and intron 5 of *AGRN* that loop to the promoter. These enhancers are enriched for H3K27ac and H3K4me1 histone marks in skeletal muscle and motor neurons, suggesting cell-type-specific activation. The intron 1 enhancer contains binding sites for the transcription factors MYOD and MEF2, consistent with the muscle-enriched expression of agrin.

A particularly notable regulatory circuit involves the long non-coding RNA (lncRNA) **NEAT1** (Nuclear Enriched Abundant Transcript 1). Li et al. (2018) demonstrated that in prostate cancer cells, NEAT1 modulates the transcriptional regulation of AGRN through the CDC5L (Cell Division Cycle 5-Like) protein. Specifically, CDC5L binds to the AGRN promoter and activates its transcription, while NEAT1 sequesters CDC5L, thereby repressing AGRN expression. This NEAT1-CDC5L-AGRN axis was shown to influence oncogenic properties including cell proliferation and DNA damage response [5].

### 1.4 Alternative Splicing and Isoforms

Alternative splicing is a defining feature of *AGRN* biology. The gene produces multiple isoforms through the differential inclusion of three alternatively spliced exons, historically designated as the **Y exon** (exon 27), **Z8 exon** (exon 31), and **Z11 exon** (exon 32) in the rat nomenclature; the human orthologs correspond to exons 27, 31, and 32 respectively. These exons are located in the C-terminal region of the protein, within the laminin G-like (LG) domains that are critical for receptor binding.

- **Y exon (exon 27)**: Encodes a 4-amino-acid insert (KSRK) in the N-terminal half of the protein. Its inclusion is enriched in neural tissues but is not required for AChR clustering activity.
- **Z8 exon (exon 31)**: Encodes an 8-amino-acid insert (ELTNEIPV) within the LG2 domain. Inclusion of Z8 is essential for the high-affinity binding of agrin to LRP4 and for the subsequent activation of MuSK. The Z8-containing isoform is referred to as "neural agrin" or "z+ agrin."
- **Z11 exon (exon 32)**: Encodes an 11-amino-acid insert (TSPGSPPGSSS) adjacent to Z8. The Z11 insert further enhances receptor binding and is present in the most active isoforms.

The generation of these neural isoforms is tightly regulated by the RNA-binding protein **PTBP1** (Polypyrimidine Tract Binding Protein 1). Bushra et al. (2023) demonstrated that PTBP1 represses the inclusion of the Y, Z8, and Z11 exons in non-neural cells by binding to specific intronic splicing silencers. In neurons, reduced PTBP1 expression or activity allows the inclusion of these exons, producing the neural agrin isoforms required for synaptogenesis [6].

Additional splicing events generate isoforms with alternative C-termini and variations in the SEA (Sperm protein, Enterokinase and Agrin) domain. The full-length isoform (isoform 1, 2,045 aa) is the canonical secreted proteoglycan. A shorter isoform lacking the N-terminal NtA domain is also produced and may have distinct subcellular localization.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The agrin protein is a modular mosaic of domains that reflect its dual roles as a basement membrane component and a signaling ligand. From the N-terminus to the C-terminus, the domain architecture is as follows:

1. **NtA domain (N-terminal Agrin domain; residues ~1–130)**: This domain mediates the binding of agrin to the γ1 chain of laminin, anchoring agrin to the basement membrane. The NtA domain adopts a globular fold stabilized by three disulfide bonds. Mutations in this domain (e.g., p.Gly45Arg) disrupt laminin binding and impair synaptic localization [1].

2. **Follistatin-like domains (FS; residues ~130–260)**: Two follistatin-like modules with homology to Kazal-type protease inhibitors. These domains may mediate protein-protein interactions and have been proposed to bind growth factors such as BMPs, though their precise function in agrin remains incompletely defined.

3. **Laminin EGF-like repeats (LE; residues ~260–500)**: A series of eight EGF-like repeats homologous to those found in laminins. These repeats contribute to the elongated, rod-like structure of the N-terminal half of agrin and may mediate interactions with other extracellular matrix (ECM) proteins.

4. **SEA domain (Sperm protein, Enterokinase and Agrin; residues ~500–620)**: A domain commonly found in heavily O-glycosylated proteins. The SEA domain in agrin contains a proteolytic cleavage site that is processed during secretion, generating a 90-kDa N-terminal fragment and a 110-kDa C-terminal fragment that remain non-covalently associated.

5. **Glycosaminoglycan (GAG) attachment region (residues ~620–1200)**: A serine/threonine-rich region containing multiple attachment sites for heparan sulfate (HS) and chondroitin sulfate (CS) chains. This region is poorly structured and highly flexible, contributing to the large hydrodynamic radius of the secreted proteoglycan. The HS chains mediate interactions with growth factors, chemokines, and other ECM components.

6. **Laminin G-like domains (LG1–LG3; residues ~1200–2045)**: The C-terminal half of agrin contains three LG domains, each of ~200 amino acids, separated by EGF-like repeats. The LG1 domain is involved in binding to α-dystroglycan. The LG2 domain contains the alternatively spliced Z8 and Z11 inserts and is the primary binding site for LRP4. The LG3 domain contributes to the stability of the LRP4 interaction and may also bind integrins.

### 2.2 Structural Biology of the LG2-LRP4 Interaction

The high-resolution structure of the agrin LG2 domain in complex with the extracellular domain of LRP4 has been solved by X-ray crystallography (PDB: 3H2T and related entries). The LG2 domain adopts a β-sandwich fold composed of two antiparallel β-sheets, with the Z8 insert forming an extended loop on the surface. This loop makes critical contacts with the β-propeller domains of LRP4, specifically the third and fourth β-propeller domains. The binding interface is dominated by electrostatic interactions and hydrogen bonds, with a dissociation constant (Kd) in the low nanomolar range for the Z8-containing isoform.

The missense mutation **p.Val1727Phe** (V1727F), located in the LG2 domain, was identified by Maselli et al. (2011) in a patient with severe CMS. Structural modeling predicted that this mutation disrupts the hydrophobic core of the LG2 domain, destabilizing the fold and reducing LRP4 binding affinity. Functional assays confirmed that the V1727F mutant agrin fails to induce AChR clustering, mimicking the phenotype of non-neural (z−) agrin [2].

### 2.3 Post-Translational Modifications

Agrin undergoes extensive post-translational processing:

- **Proteolytic cleavage**: The SEA domain is cleaved by an autoproteolytic mechanism during secretion. Additionally, the protease neurotrypsin (PRSS12) cleaves agrin at the α-site (between residues 1750 and 1751) and β-site (between residues 1770 and 1771) in the LG3 domain, releasing a 22-kDa C-terminal fragment (CAF; C-terminal Agrin Fragment). Plasma CAF levels are used as a biomarker for NMJ dysfunction and sarcopenia [3].
- **Glycosylation**: The GAG attachment region is modified with heparan sulfate chains (average 2–3 chains per molecule) and, in some isoforms, chondroitin sulfate. N-linked glycosylation occurs at multiple sites in the LG domains.
- **Disulfide bond formation**: The NtA, FS, LE, and LG domains contain conserved cysteine residues that form intramolecular disulfide bonds, stabilizing the modular structure.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load AGRN (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O00468)

The interactive visualizer allows users to explore the experimentally determined structures of agrin domains, including the LG2 domain in complex with LRP4 (PDB: 3H2T), the NtA domain (PDB: 1PZ7), and the SEA domain. Users can highlight pathogenic mutation sites, color by secondary structure, and measure atomic distances within the binding interfaces.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Agrin-LRP4-MuSK Signaling Axis at the Neuromuscular Junction

The canonical function of agrin is the induction of AChR clustering at the postsynaptic membrane of the NMJ. This process is initiated when neural agrin (Z8/Z11-containing isoform) is released from motor neuron terminals and binds to LRP4, a single-pass transmembrane protein expressed on the muscle surface. The agrin-LRP4 complex then recruits and activates MuSK, a receptor tyrosine kinase. MuSK activation triggers a signaling cascade that includes:

1. **Dok-7 (Downstream of Kinase 7)**: A cytoplasmic adaptor protein that binds to the juxtamembrane region of MuSK and is essential for MuSK activation. Dok-7 dimerizes and stabilizes the active conformation of MuSK.
2. **Rapsyn**: A peripheral membrane protein that links AChRs to the cytoskeleton. Rapsyn is recruited to the postsynaptic membrane by MuSK signaling and is required for AChR clustering.
3. **Rho family GTPases**: Activation of Rac1 and Cdc42 promotes actin polymerization and the reorganization of the postsynaptic cytoskeleton.
4. **PAK1 (p21-Activated Kinase)**: A downstream effector of Rac1/Cdc42 that phosphorylates and activates downstream targets involved in cytoskeletal remodeling.

The signaling cascade is tightly regulated by negative feedback. For example, the E3 ubiquitin ligase **PDZRN3** ubiquitinates MuSK and targets it for degradation, limiting the duration of signaling. Additionally, the protein tyrosine phosphatase **SHP2** dephosphorylates MuSK, attenuating its activity.

### 3.2 Agrin in the Central Nervous System

Beyond the NMJ, agrin is expressed in the central nervous system (CNS), where it regulates multiple processes:

- **Hippocampal neurogenesis**: Zhang et al. (2019) demonstrated that agrin signaling through LRP4 and the receptor tyrosine kinase Ror2 promotes the proliferation of neural stem/progenitor cells (NSPCs) in the adult hippocampus. Knockdown of agrin, LRP4, or Ror2 in the dentate gyrus reduced NSPC proliferation, implicating this pathway in adult neurogenesis and potentially in learning and memory [4].
- **Blood-brain barrier integrity**: Agrin is a major heparan sulfate proteoglycan of the vascular basement membrane in the brain. Rauch et al. (2011) showed that altered agrin expression in mice affects the deposition of β-amyloid and the expression of aquaporin-4 (AQP4) at the BBB, linking agrin to the pathogenesis of Alzheimer's disease [5].
- **Synaptic plasticity**: Agrin is expressed at central synapses, where it modulates the function of glutamatergic receptors. The CRABP1-CaMKII-Agrn axis has been shown to regulate the maintenance of the NMJ in spinal motor neurons, with retinoic acid signaling influencing agrin expression [6].

### 3.3 Agrin in Cardiac and Skeletal Muscle Function

Agrin regulates the activity of the **α3 subunit of the Na,K-ATPase** in cardiac myocytes. Hilgenberg et al. (2009) demonstrated that agrin binds to the α3 Na,K-ATPase and increases its activity, thereby modulating cardiac myocyte contractility. This interaction is independent of the LRP4/MuSK pathway and represents a novel function of agrin in the heart [1].

In skeletal muscle, agrin is required for the maintenance of the NMJ and for muscle mass. Pratt et al. (2023) found that genetic variants in AGRN and PRSS12 (encoding neurotrypsin) are associated with muscle mass, strength, and plasma CAF concentration in older adults, implicating the agrin/neurotrypsin axis in sarcopenia [3].

### 3.4 Agrin in the Immune System and Inflammation

Agrin is expressed by immune cells, including macrophages and T cells, and modulates immune responses. In the context of systemic lupus erythematosus (SLE), Lv et al. (2023) performed a bioinformatics analysis showing that AGRN expression is dysregulated in SLE and correlates with immune infiltration in various cancers [2]. In breast cancer, suppression of AGRN enhances CD8+ T cell recruitment and inhibits tumor progression, suggesting that agrin acts as an immune checkpoint molecule [3].

### 3.5 Protein-Protein Interaction Network

The agrin interactome includes both extracellular and intracellular partners:

| Interactor | Type | Function |
|---|---|---|
| LRP4 | Transmembrane receptor | Primary signaling receptor; mediates MuSK activation |
| MuSK | Receptor tyrosine kinase | Downstream effector; essential for AChR clustering |
| Laminin (γ1 chain) | ECM protein | Anchors agrin to basement membrane via NtA domain |
| α-Dystroglycan | Transmembrane glycoprotein | Binds LG1 domain; links ECM to cytoskeleton |
| Integrins (αVβ3, α7β1) | Transmembrane receptors | Mediate cell adhesion and signaling |
| Na,K-ATPase (α3 subunit) | Ion pump | Regulates cardiac contractility |
| Neurotrypsin (PRSS12) | Secreted protease | Cleaves agrin to release CAF |
| Ror2 | Receptor tyrosine kinase | Mediates agrin signaling in hippocampal NSPCs |
| CDC5L | Transcription factor | Regulates AGRN transcription (via NEAT1) |

STRING analysis reveals a high-confidence interaction network centered on LRP4, MuSK, and DOK7, with additional connections to ECM proteins (COL4A1, LAMA2) and signaling molecules (DAG1, ITGB1).

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Congenital Myasthenic Syndromes (CMS)

CMS are a heterogeneous group of inherited disorders of the NMJ caused by mutations in genes encoding proteins essential for neuromuscular transmission. AGRN is one of the 35–40 genes associated with CMS [4, 5]. Mutations in AGRN account for approximately 1–2% of CMS cases and are inherited in an autosomal recessive manner.

#### 4.1.1 Clinical Phenotype

Patients with AGRN-related CMS typically present in infancy or early childhood with:

- **Ptosis** (drooping eyelids)
- **Ophthalmoparesis** (weakness of extraocular muscles)
- **Bulbar weakness** (difficulty swallowing and speaking)
- **Proximal limb weakness**
- **Fatigable weakness** (worsening with exertion)
- **Respiratory insufficiency** in severe cases

A distinctive phenotype is the **"head drop"** sign, where patients have prominent neck extensor weakness. Karakaya et al. (2017) reported a patient with a novel missense variant presenting with head drop as the predominant feature [6]. Some patients develop distal myopathy, as described by Bamaga et al. (2017) [1].

#### 4.1.2 Genotype-Phenotype Correlations

The severity of AGRN-related CMS correlates with the location and nature of the mutation:

- **Null variants (nonsense, frameshift, large deletions)**: These typically cause severe, early-onset CMS or lethal FADS. Geremek et al. (2019) reported a case of lethal FADS caused by a frameshift variant in trans with a 148-kb deletion encompassing exons 3–36 of AGRN [2].
- **Missense variants in the NtA domain**: Disrupt laminin binding and result in moderate CMS. Wang et al. (2020) described a patient with novel NtA and LG1 mutations [1].
- **Missense variants in the LG2 domain**: Impair LRP4 binding and AChR clustering. The V1727F mutation is a canonical example [2]. Xi et al. (2017) identified novel SEA and LG2 mutations causing CMS [3].
- **Missense variants in the LG3 domain**: May affect neurotrypsin cleavage and CAF release, leading to a milder phenotype.

#### 4.1.3 Specific Mutations Reported

| Mutation | Protein Change | Domain | Phenotype | Reference |
|---|---|---|---|---|
| c.1057C>T | p.Gln353Ter (Q353X) | N-terminal | Severe CMS | [2] |
| c.5179G>T | p.Val1727Phe (V1727F) | LG2 | Severe CMS | [2] |
| c.133G>A | p.Gly45Arg | NtA | Moderate CMS | [1] |
| c.1762A>G | p.Lys588Glu | SEA | CMS with distal myopathy | [3] |
| c.5176A>G | p.Thr1726Ala | LG2 | CMS | [3] |
| c.1234C>T | p.Arg412Ter | LE | Severe CMS | [4] |
| c.7096_7097del | p.Leu2366ValfsTer | LG3 | Lethal FADS | [2] |
| c.1552C>T | p.Arg518Ter | SEA | CMS | [5] |
| c.5128G>A | p.Gly1710Arg | LG2 | CMS with head drop | [6] |
| c.6025C>T | p.Arg2009Trp | LG3 | CMS | [6] |

### 4.2 Lethal Fetal Akinesia Deformation Sequence (FADS)

FADS is a severe prenatal phenotype characterized by decreased fetal movement, joint contractures (arthrogryposis), pulmonary hypoplasia, and facial anomalies. Null variants in AGRN cause lethal FADS due to the complete absence of agrin function at the developing NMJ [2]. This phenotype is more severe than typical CMS and is often detected prenatally by ultrasound.

### 4.3 Myasthenia Gravis (MG) Risk Locus

MG is an autoimmune disorder caused by antibodies against components of the NMJ, most commonly the AChR. A genome-wide association study (GWAS) by Topaloudi et al. (2021) identified AGRN as a novel risk locus for MG [1]. The associated variant (rs41282690) is located in an intronic region of AGRN and may affect gene expression or splicing. This finding suggests that genetic variation in AGRN contributes to the susceptibility to autoimmune NMJ disorders.

### 4.4 Other Neurological and Neuromuscular Conditions

- **Catecholaminergic polymorphic ventricular tachycardia (CPVT)**: Jaouadi et al. (2021) identified variants in AGRN and RPL3L in a patient with CPVT, suggesting a possible role for AGRN in cardiac arrhythmias and digenic inheritance [2].
- **High myopia**: A mutational screening of AGRN in a Chinese cohort of 103 patients with nonsyndromic high myopia identified potential pathogenic variants, though the association remains tentative [3].
- **Dancing Doberman Disease**: A homozygous missense variant in AGRN was identified in Doberman Pinscher dogs with a hereditary neuromuscular disorder, providing a large animal model for AGRN-related CMS [4].

### 4.5 Cancer

Agrin is overexpressed in multiple cancer types, where it promotes tumor progression, invasion, and metastasis:

- **Colorectal cancer (CRC)**: AGRN is identified as a basement membrane-associated gene with prognostic significance in CRC. Li et al. (2024) showed that high AGRN expression correlates with poor prognosis and immune infiltration [5]. Xiang et al. (2024) developed a basement membrane-related gene signature that includes AGRN for predicting prognosis and drug sensitivity in CRC [6]. Chen et al. (2024) demonstrated a correlation between AGRN expression and perineural invasion in colon cancer [1].
- **Breast cancer**: Tao et al. (2024) showed that AGRN is upregulated in breast cancer and that its suppression enhances CD8+ T cell recruitment and inhibits tumor progression [3]. AGRN is also part of a vasculature gene signature predictive of breast cancer survival [2].
- **Gastrointestinal tumors**: Ni et al. (2025) identified AGRN as a key gene in a universal epithelial-mesenchymal transition (EMT) program across gastrointestinal tumors [3].
- **Hepatocellular carcinoma (HCC)**: AGRN is part of an extracellular matrix gene-related signature associated with prognosis and therapy response in HCC [4].
- **Lung adenocarcinoma**: AGRN is included in glycolysis-related gene signatures for predicting metastasis and survival in lung adenocarcinoma [5, 6].
- **Esophageal cancer**: AGRN is part of a basement membrane-related regulator model for prognosis prediction in esophageal cancer [1].
- **Prostate cancer**: The NEAT1-CDC5L-AGRN transcriptional regulation circuit contributes to oncogenic properties in prostate cancer cells [5].

### 4.6 Other Diseases

- **Chronic obstructive pulmonary disease (COPD)**: Agrin is overexpressed in COPD, and the BET inhibitor JQ1 has been proposed as a potential therapeutic option [2].
- **COVID-19**: Plasma AGRN levels are associated with hospitalization risk in COVID-19 patients, suggesting a role in disease severity [3].
- **Liver fibrosis**: Plasma AGRN is a novel diagnostic biomarker for hepatitis B virus-related chronic hepatitis and liver fibrosis/cirrhosis [4].
- **Alzheimer's disease**: Agrin is involved in BBB integrity and β-amyloid deposition [5].
- **Sarcopenia**: AGRN and PRSS12 variants are associated with muscle mass and strength in older adults [3].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 SARS-CoV-2 and COVID-19

The COVID-19 pandemic has highlighted the role of the ECM and proteoglycans in viral infection. Agrin, as a heparan sulfate proteoglycan, may interact with SARS-CoV-2 spike protein, which binds to heparan sulfate as a co-receptor for ACE2. McLarnon et al. (2024) identified plasma AGRN as one of four proteins (along with LGALS9, LAMP3, and PRSS8) that predict hospitalization risk in COVID-19 patients [3]. The mechanism may involve agrin-mediated modulation of the immune response or direct effects on viral entry.

### 5.2 Hepatitis B Virus (HBV)

Agrin is a component of the hepatic basement membrane, and its expression is altered in chronic HBV infection. Ai et al. (2023) demonstrated that plasma AGRN levels are elevated in patients with HBV-related chronic hepatitis and liver fibrosis/cirrhosis, and proposed AGRN as a diagnostic biomarker [4]. The mechanism may involve agrin's role in the hepatic stellate cell activation and ECM remodeling that accompanies fibrosis.

### 5.3 Bacterial Pathogens

While direct interactions between agrin and bacterial effectors have not been extensively characterized, agrin's role in basement membrane integrity suggests it may influence bacterial invasion across epithelial and endothelial barriers. The heparan sulfate chains of agrin can bind to bacterial adhesins, potentially facilitating or inhibiting bacterial attachment.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Strategies for AGRN-Related CMS

Currently, there is no cure for AGRN-related CMS, but symptomatic treatments are available:

- **Acetylcholinesterase inhibitors (AChEIs)**: Drugs such as pyridostigmine are the first-line treatment for many CMS subtypes. However, their efficacy in AGRN-related CMS is variable and may be limited.
- **Ephedrine and salbutamol**: Sympathomimetic agents that have shown benefit in some CMS patients, particularly those with MuSK or Dok-7 mutations. Their use in AGRN-related CMS is being explored.
- **3,4-Diaminopyridine (3,4-DAP)**: A potassium channel blocker that enhances acetylcholine release at the NMJ. It may be used as adjunctive therapy.

### 6.2 MuSK Agonist Antibodies

A promising therapeutic approach for AGRN-related CMS is the use of **MuSK agonist antibodies**. Ho et al. (2025, 2026) demonstrated that a MuSK agonist antibody can improve NMJ structure and muscle strength in mouse models of CMS caused by mutations in AGRN and COLQ [1, 5, 6]. The antibody bypasses the need for agrin-LRP4 signaling by directly activating MuSK, thereby restoring AChR clustering. This gene-specific response suggests that MuSK agonist antibodies could be a targeted therapy for AGRN-related CMS.

### 6.3 Modulation of the AChR Clustering Pathway

Spendiff et al. (2020) investigated the modulation of the AChR clustering pathway as a therapeutic strategy for CMS. They showed that treatment with a MuSK agonist antibody or with agrin itself can improve NMJ structure and muscle strength in a mouse model of CMS [2]. This approach may be applicable to AGRN-related CMS.

### 6.4 BET Inhibitors for COPD

In COPD, agrin is overexpressed, and the BET inhibitor **JQ1** has been shown to reduce agrin expression and ameliorate disease features in experimental models [2]. JQ1 inhibits the bromodomain and extra-terminal (BET) proteins, which are epigenetic readers that regulate gene expression. This represents a potential therapeutic option for COPD patients with agrin overexpression.

### 6.5 Cancer Therapeutics Targeting AGRN

Given the role of agrin in tumor progression, several strategies are being explored:

- **Monoclonal antibodies**: Antibodies targeting agrin or its receptors (LRP4, MuSK) could disrupt tumor-promoting signaling.
- **siRNA/ASO therapies**: Suppression of AGRN expression using small interfering RNA (siRNA) or antisense oligonucleotides (ASOs) has been shown to inhibit breast cancer progression and enhance CD8+ T cell recruitment [3].
- **Immune checkpoint modulation**: Since AGRN suppression enhances CD8+ T cell recruitment, combining AGRN inhibition with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) may improve anti-tumor immunity.

### 6.6 Gene Therapy

Gene therapy approaches for AGRN-related CMS are in preclinical development. Adeno-associated virus (AAV) vectors encoding the full-length or mini-agrin gene could potentially restore agrin function at the NMJ. The large size of the AGRN coding sequence (~6.3 kb) poses a challenge for AAV packaging, but the use of dual-vector systems or truncated but functional agrin variants (e.g., mini-agrin containing the NtA and LG domains) is being explored.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession / ID | Link |
|---|---|---|
| **NCBI Gene** | 375790 | https://www.ncbi.nlm.nih.gov/gene/375790 |
| **Ensembl** | ENSG00000188157 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188157 |
| **UniProt** | O00468 | https://www.uniprot.org/uniprotkb/O00468 |
| **RCSB PDB** | 3H2T (LG2-LRP4 complex), 1PZ7 (NtA domain) | https://www.rcsb.org/ |
| **OMIM** | 103320 | https://www.omim.org/entry/103320 |
| **ClinVar** | AGRN | https://www.ncbi.nlm.nih.gov/clinvar/?term=AGRN |
| **HGNC** | 329 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:329 |
| **Gene Ontology (GO)** | GO:0005576 (extracellular region), GO:0007165 (signal transduction), GO:0007528 (neuromuscular junction development), GO:0007155 (cell adhesion) | https://www.ebi.ac.uk/QuickGO/ |
| **STRING** | AGRN (human) | https://string-db.org/network/9606.ENSP00000358158 |
| **BioGRID** | AGRN | https://thebiogrid.org/ |
| **GTEx Portal** | AGRN | https://gtexportal.org/home/gene/AGRN |
| **Human Protein Atlas** | AGRN | https://www.proteinatlas.org/ENSG00000188157-AGRN |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Ni, Z., Zhu, P., Liu, L., Wang, H., Zhou, J., Wang, X., Wang, S., Zhu, L., Zhang, S., Zhou, Y., Ge, B., Huang, Q., & Huang, C. (2025). Single‐Cell Transcriptomic Analysis Reveals Epithelial‐Mesenchymal Transition and Key Gene AGRN as a Universal Programme in Gastrointestinal Tumours by an Artificial Intelligence‐Derived Prognostic Index. *Med Research*. https://www.semanticscholar.org/paper/6ef16e7acbe11bf15f1be7a05835d107e03feb24

[2] Li, J., You, D., Hu, L., Yang, Y., Gao, S., & Bai, W. (2024). Identification and validation of basement membrane‐associated gene AGRN as prognostic and immune‐associated biomarkers in colorectal cancer patients. *Journal of Cellular and Molecular Medicine*. https://www.semanticscholar.org/paper/011c869e441d03b56becbd216a9c79748fdcdcb0

[3] Lv, R., Duan, L., Gao, J., Si, J., Feng, C., Hu, J., & Zheng, X. (2023). Bioinformatics-based analysis of the roles of basement membrane-related gene AGRN in systemic lupus erythematosus and pan-cancer development. *Frontiers in Immunology*. https://www.semanticscholar.org/paper/b8deaf3e15ddd5da3d9e085dbccfa2c2e2d67950

[4] Gan, S., Yang, H., Xiao, T., Pan, Z., & Wu, L. (2020). AGRN Gene Mutation Leads to Congenital Myasthenia Syndromes: A Pediatric Case Report and Literature Review. *Neuropediatrics*. https://www.semanticscholar.org/paper/f6f56edbbc4fbf38ffd1de0f15a1fadf6549dd78

[5] Karakaya, M., Ceyhan-Birsoy, O., Beggs, A., & Topaloğlu, H. (2017). A Novel Missense Variant in the AGRN Gene; Congenital Myasthenic Syndrome Presenting With Head Drop. *Journal of Clinical Neuromuscular Disease*. https://www.semanticscholar.org/paper/1855761f4ffdaf8a09a2585545ede681a1455e0e

[6] Zhang, A.,